Needham & Company Reiterates Phathom Pharmaceuticals (PHAT) at Buy, Expects Approval of vonoprazan for H.pylori, Sees It as Laying Groundwork for Potential Approval in EE
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer reiterated a Buy rating and $55.00 price target on Phathom Pharmaceuticals (NASDAQ: PHAT), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
